Lymphomas of the Parotid Gland in Denmark: A Nationwide Cohort Study
The Laryngoscope · 2025
DOI: 10.1002/lary.31929 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Laryngoscope, 2025. Verfasst von Fahd Al-Shahrestani und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology and Maxillofacial Surgery, Zealand University Hospital, Køge, Denmark. Hauptthemen laut MEDLINE: Parotid Neoplasms, Lymphoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
Objective
We examined the epidemiology of parotid gland lymphomas (PGL), the incidence, survival rates, clinical features, and association with primary Sjögren's syndrome (pSS).
Methods
This retrospective nationwide cohort study analyzed data from Danish patients diagnosed with PGL between 2000 and 2020. Data were collected from medical records, the National Pathology Register, and the Danish lymphoma database. Statistical analyses included Kaplan–Meier curves, log‐rank tests, and Cox proportional hazards models.
Results
A total of 433 patients were included. The incidence rate was 0.39 per 100,000 person‐years, with PGL constituting 1.9% of all non‐Hodgkins lymphoma in Denmark. The average annual incidence was 2.7% (incidence rate ratio = 1.027, p < 0.01). Follicular lymphoma (FL) was the most common subtype with 154 cases (35.6%), followed by large B‐cell lymphoma (LBCL) with 119 cases (27.5%), and extranodal marginal zone lymphoma (EMZL) with 84 cases (19.4%). The median overall survival (OS) for FL was 9.5 years (95% CI 6.9–10.2), with 5‐year and 10‐year OS rates of 70% and 44%, respectively. For LBCL, the median OS was 7.8 years (95% CI 5.0–8.8), with 5‐year and 10‐year OS rates of 59% and 33%. EMZL had a median OS of 12.8 years (95% CI 9.0–16.3), with 5‐year and 10‐year OS rate of 83% and 55%. EMZL was significantly associated with pSS, relative risk 21.97 (95% CI 2.81–171.53). Advanced age, B symptoms, and elevated LDH levels were significantly linked to poorer overall survival.
Conclusion
This study offers new epidemiological, clinical, and prognostic insights, with a focus on their association with pSS. Level of Evidence 3 Laryngoscope , 135:1391–1400, 2025
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otorhinolaryngology and Maxillofacial Surgery, Zealand University Hospital, Køge, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- Department of Hematology, Odense University Hospital, Odense, Denmark.
- Department of Hematology, Vejle Hospital, Sygehus Lillebaelt, Vejle, Denmark.
- Department of Hematology, Gødstrup Hospital, Herning, Denmark.
- Department of Hematology, Aalborg University Hospital, Aalborg, Denmark.
ORCID-Profile: Fahd Al-Shahrestani, Ahmed Ehsan Al-Khafaf, Zain Asheer, Jelena Jelicic, Anne Kathrine Aalling Sørensen, Lars Møller Pedersen, Lise Mette Rahbek Gjerdrum, Steffen Heegaard, Preben Homøe
Zitieren
APA
Al-Shahrestani, F., Al-Khafaf, A. E., Asheer, Z., Jelicic, J., Chanchiri, I., Blocher, C. E., Aalling Sørensen, A. K., Møller Pedersen, L., Gjerdrum, L. M. R., Heegaard, S., & Homøe, P. (2025). Lymphomas of the Parotid Gland in Denmark: A Nationwide Cohort Study. The Laryngoscope. https://doi.org/10.1002/lary.31929
Vancouver
Al-Shahrestani F, Al-Khafaf AE, Asheer Z, Jelicic J, Chanchiri I, Blocher CE, et al. Lymphomas of the Parotid Gland in Denmark: A Nationwide Cohort Study. The Laryngoscope. 2025. doi:10.1002/lary.31929
BibTeX
@article{AlShahrestani2025,
author = {Al-Shahrestani, Fahd and Al-Khafaf, Ahmed Ehsan and Asheer, Zain and Jelicic, Jelena and Chanchiri, Iman and Blocher, Catharina E and Aalling Sørensen, Anne Kathrine and Møller Pedersen, Lars and Gjerdrum, Lise Mette Rahbek and Heegaard, Steffen and Homøe, Preben},
title = {Lymphomas of the Parotid Gland in Denmark: A Nationwide Cohort Study},
journal = {The Laryngoscope},
year = {2025},
doi = {10.1002/lary.31929}
}
EUVIMED